» Articles » PMID: 25009648

Locally-advanced Unresected Uterine Leiomyosarcoma with Triple-modality Treatment Combining Radiotherapy, Chemotherapy and Hyperthermia: A Case Report

Overview
Journal Oncol Lett
Specialty Oncology
Date 2014 Jul 11
PMID 25009648
Authors
Affiliations
Soon will be listed here.
Abstract

Advanced uterine leiomyosarcoma (LMS) is a rare and extremely aggressive disease. In patients with advanced and unresected uterine LMS, multidisciplinary therapy is the best treatment option, although no consensus exists on the efficacy of the treatment. The present study describes the case of a 41-year-old female who underwent laparotomy due to a large uterine tumor. Exploratory laparotomy revealed a large tumor that had extended from the pelvic wall to the outside of the pelvis and then invaded the colon. Large residual tumors remained present in the pelvis following suboptimal debulking surgery. Subsequent to surgery, the patient was treated with adjuvant radiotherapy, followed by chemotherapy with regional whole pelvis hyperthermia (HT). Computed tomography revealed stable disease prior and subsequent to combination treatment. While treatment was being administered for third/fourth-degree burns and subcutaneous fatty necrosis, the patient developed multi-organ failure and succumbed. The present case report describes the potential for using a combination of chemotherapy, HT and radiotherapy in patients with LMS. The development of an effective protocol is required for the administration of chemotherapy, HT and radiotherapy in patients with advanced unresected LMS.

References
1.
Rose P, Blessing J, Soper J, Barter J . Prolonged oral etoposide in recurrent or advanced leiomyosarcoma of the uterus: a gynecologic oncology group study. Gynecol Oncol. 1998; 70(2):267-71. DOI: 10.1006/gyno.1998.5080. View

2.
SLAYTON R, Blessing J, Angel C, Berman M . Phase II trial of etoposide in the management of advanced and recurrent leiomyosarcoma of the uterus: a Gynecologic Oncology Group Study. Cancer Treat Rep. 1987; 71(12):1303-4. View

3.
Park J, Park S, Kim D, Kim J, Kim Y, Kim Y . The impact of tumor morcellation during surgery on the prognosis of patients with apparently early uterine leiomyosarcoma. Gynecol Oncol. 2011; 122(2):255-9. DOI: 10.1016/j.ygyno.2011.04.021. View

4.
Westermann A, Jones E, Schem B, van der Steen-Banasik E, Koper P, Mella O . First results of triple-modality treatment combining radiotherapy, chemotherapy, and hyperthermia for the treatment of patients with stage IIB, III, and IVA cervical carcinoma. Cancer. 2005; 104(4):763-70. DOI: 10.1002/cncr.21128. View

5.
Garcia-Carbonero R, Supko J, Manola J, Seiden M, Harmon D, Ryan D . Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol. 2004; 22(8):1480-90. DOI: 10.1200/JCO.2004.02.098. View